Results 41 to 50 of about 71,439 (210)

Acute Generalized Exanthematous Pustulosis Caused by Erlotinib in a Patient with Lung Cancer

Case Reports in Oncology, 2021
Acute generalized exanthematous pustulosis (AGEP) is a rare drug-related adverse skin reaction caused mainly by antibiotics. Erlotinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) used to treat lung cancer.
Natsuko Komiya, Koichiro Takahashi, Go Kato, Mio Kubota, Hiroki Tashiro, Chiho Nakashima, Tomomi Nakamura, Kentaro Iwanaga, Shinya Kimura, Naoko Sueoka-Aragane   +9 more
doaj   +1 more source

Genetic Association of Drug Response to Erlotinib in Chinese Advanced Non-small Cell Lung Cancer Patients

Frontiers in Pharmacology, 2018
The efficacy of erlotinib treatment for advanced non-small cell lung cancer (NSCLC) is due to its action as an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). Patients treated with erlotinib experience different drug responses. The
Cong Wang, Cong Wang, Fang Chen, Fang Chen, Yichen Liu, Qingqing Xu, Liang Guo, Xiaoqing Zhang, Yunfeng Ruan, Ye Shi, Lu Shen, Mo Li, Huihui Du, Xiaofang Sun, Jingsong Ma, Lin He, Shengying Qin, Shengying Qin, Shengying Qin   +18 more
doaj   +1 more source

Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53 independent pathways [PDF]

, 2014
Most cancer cells use aerobic glycolysis to fuel their growth. The enzyme lactate dehydrogenase-A (LDH-A) is key to cancer’s glycolytic phenotype, catalysing the regeneration of nicotinamide adenine dinucleotide (NAD þ ) from reduced nicotinamide adenine
Allison, Simon J., Granchi, C., Knight, J.R.P., Milner, J., Minutolo, F., Phillips, R.M., Rani, R.   +6 more
core   +1 more source

Erlotinib can halt adenine induced nephrotoxicity in mice through modulating ERK1/2, STAT3, p53 and apoptotic pathways

Scientific Reports, 2020
Renal fibrosis is a failed regenerative process that facilitates chronic kidney disease progression. The current study was designed to study the effect of erlotinib, a receptor tyrosine kinase inhibitor, on the progression of renal fibrosis.
Ahmed M. Awad, Mohamed A. Saleh, Nashwa M. Abu-Elsaad, Tarek M. Ibrahim   +3 more
doaj   +1 more source

Partial Response to Platinum Doublets in Refractory EGFR-Positive Non-Small Cell Lung Cancer Patients after RRx-001: Evidence of Episensitization. [PDF]

, 2016
RRx-001, an experimental systemically non-toxic epi-immunotherapeutic agent, which potentiates the resensitization of resistant cancer cells to formerly effective therapies, is under active investigation in several clinical trials that are based on ...
Brzezniak, Christina, Cabrales, Pedro, Caroen, Scott Z, Carter, Corey A, Degesys, Aiste, Jenkins, John, Oronsky, Bryan T, Reid, Tony, Scicinski, Jan J   +8 more
core   +3 more sources

Disparity in the Markers of Affordability Across Targeted‐ and Immune‐Therapy Drugs Used in Head and Neck Cancers

Head &Neck, EarlyView.
ABSTRACT Background The expanding use of systemic therapies for recurrent and metastatic head and neck cancer has raised major concerns regarding affordability and equitable access, particularly across countries with differing income levels and health financing structures.
Arjun Gurmeet Singh, Labani Kole, Richard Sullivan, Shwetabh Sinha, Rathan Shetty, Poonam Joshi, Sudhir Nair, Sarbani Ghosh Laskar, Kumar Prabhash, Pankaj Chaturvedi   +9 more
wiley   +1 more source

MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma [PDF]

, 2018
Background The high incidence and mortality of lung tumours is a major health problem. Therefore, the identification both of biomarkers predicting efficacy for therapies in use and of novel efficacious therapeutic agents is crucial to increase patient ...
Carnero Moya, Amancio, Ferrer, Irene, García Heredia, José Manuel, Molina Pinelo, Sonia, Pérez, Marco, Quintanal Villalonga, Álvaro Diego   +5 more
core   +1 more source

Aliphatic Poly(Carbonate)s with Acid Responsive Release Mechanisms for Micellar Anti‐Tumor Drug Delivery

Macromolecular Rapid Communications, EarlyView.
Micellar systems based on biodegradable aliphatic polycarbonates and acid‐responsive triggers enhance drug solubility, stability, and tumor‐selective release. This review covers micelles with acid‐cleavable drug linkages and those that disassemble via acid‐sensitive functionalities.
Adrian V. Hauck, Lutz Nuhn
wiley   +1 more source

Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study

Therapeutic Advances in Medical Oncology, 2022
Background: Although bevacizumab in combination with afatinib or erlotinib is an effective and safe first-line therapy for advanced epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), there are very few clinical data ...
Suey-Haur Lee, Yu-Ching Lin, Li-Chung Chiu, Jia-Shiuan Ju, Pi-Hung Tung, Allen Chung-Cheng Huang, Shih-Hong Li, Yueh-Fu Fang, Chih-Hung Chen, Scott Chih-Hsi Kuo, Chin-Chou Wang, Cheng-Ta Yang, Ping-Chih Hsu   +12 more
doaj   +1 more source

Erlotinib: Um caso clínico de sucesso e algumas notas sobre a toxicidade hepática

Revista Portuguesa de Pneumologia, 2008
Resumo: Apresenta-se o caso clínico de uma mulher com adenocarcinoma do pulmão em que se conseguiu o controlo da doença, durante quinze meses, com erlotinib em segunda linha.
Agostinho Costa
doaj   +1 more source